The Erythropoietin NeuroProtective Effect: Assessment in CABG Surgery (TENPEAKS)
Status:
Completed
Trial end date:
2005-05-01
Target enrollment:
Participant gender:
Summary
Context: Neurocognitive dysfunction complicates coronary artery bypass graft surgery.
Neurocognitive dysfunction is a measurable problem with thinking. Erythropoietin may be a
neuroprotectant.
Objective: To investigate the feasibility and safety of three doses of human recombinant
erythropoietin to reduce neurocognitive dysfunction in coronary artery bypass graft patients.